Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Dept. of Urology, Medical University of Vienna, 18-20, Xähringer-Gürte, 1090 Vienna, Austria.
Screening for prostate cancer is currently based on the assessment of blood prostate specific antigen (PSA). Although PSA was shown to be an adequate tool in prostate cancer screening, beginning from 4.0 ng/mL, its specificity is less significant. In men with a PSA between 4.0 and 10 ng/mL its predictive value is low. Therefore, there is a need for new instruments likely to improve the specificity of blood PSA levels between 4.0 and 10 ng/mL and the screening for prostate cancer in subjects with low PSA. Recent data are reviewed.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on